Company: Complete Genomics
Based: Mountain View, CA
Investors: Sands Capital, Essex Woodlands, OVP Venture Partners, Prospect Venture Partners, OrbiMed Advisors, Highland Capital Management and Enterprise Partners
Scoop: Mountain View, CA-based Complete Genomics reported last summer it had raised $39 million in a new venture round--its fifth. New investor Sands Capital led this round of financing and was joined by existing investors Essex Woodlands, OVP Venture Partners, Prospect Venture Partners, OrbiMed Advisors, Highland Capital Management and Enterprise Partners.
Complete Genomics has developed and commercialized an innovative DNA sequencing platform. And it has said it wants to offer developers genome sequencing for less than $1,000, a price that would make the assembly-line technology available to virtually anyone looking to use it in development programs. However, in November, the company priced its IPO at $9, well under the $12 to $14 range it had hoped for.
Last Thursday, shares of the company saw unusually high trading volume. According to American Banking & Market News approximately 134,503 shares changed hands during mid-day trading, an increase of 122.27 percent from the previous session. The stock last traded at $7.38.